SeaStar Medical Holding Corporation ICU

SeaStar Medical Holding Corp announced that H. David Humes, M.D., won the University of Michigan's 2026 Distinguished University Innovator of the Year for developing the Selective Cytopheretic Device (SCD) therapy, commercialized as QUELIMMUNE (SCD-PED) for critically ill pediatric AKI with sepsis. QUELIMMUNE, approved in 2024 under a Humanitarian Device Exemption, has shown a ~50% reduction in mortality at 60 days in trials and a 77% survival vs historical controls in two studies; no dialysis required for survivors and ~87.5% with normal kidney function at Day 60. SeaStar's ongoing NEUTRALIZE-AKI pivotal adult trial (n=339) evaluates SCD with CRRT, aiming for 90-day mortality or dialysis dependency as primary endpoint. The company notes additional indications in development and a total of 6 FDA Breakthrough Designations. SeaStar plans to expand beyond pediatrics as pipeline matures. Validation from a prestigious university award and positive QUELIMMUNE data with expansion into adult indications signal meaningful upside for SeaStar.

SeaStar Medical Holding Corporation reports ongoing revenue increases for its QUELIMMUNE® product. Continued revenue growth from QUELIMMUNE® indicates steady commercial traction without signaling major strategic shifts.

SeaStar Medical Holding Corp (ICU) Q2 2026 earnings call highlighted Qualimmune revenue results and associated financial updates. Q2 earnings highlights on Qualimmune revenue can moderately affect near-term financial outlook and investor sentiment.

SeaStar Medical (ICU) released its Q2 2026 earnings call transcript covering quarterly financial results, operational updates, and forward outlook. Earnings call transcripts deliver key financial metrics and guidance that typically drive immediate stock price moves and alter investor views on trajectory.

SeaStar Medical Holding Corporation reported second quarter 2026 financial results and provided business updates. Quarterly earnings releases typically influence near-term stock sentiment and valuation without major strategic shifts.

SeaStar Medical supports advances in critical care for pediatric patients with acute kidney injury. Company's role in pediatric AKI care advances may boost its medical device market position and investor interest.

SeaStar Medical obtains new ICD-10-PCS codes for its SCD therapy treating acute kidney injury, enabling standardized billing and reimbursement. New ICD-10-PCS codes directly support reimbursement and adoption of SCD therapy, materially improving commercial prospects.

SeaStar Medical Holding Corporation (ICU) reported a 69% year-over-year revenue increase. 69% YoY revenue growth signals strong expansion likely to boost investor sentiment and alter company trajectory.

SeaStar Medical Holding Corp (ICU) Q1 2026 earnings call highlights strong revenue growth. Strong revenue growth in Q1 2026 indicates significant positive momentum for ICU's financial trajectory and market sentiment.

SeaStar Medical Holding Corporation (ICU) released Q2 2026 earnings call summary detailing financial results, operational updates, and forward guidance. Q2 earnings call summary provides key financial performance and outlook data with moderate influence on investor sentiment and trajectory.

SeaStar Medical Holding Corporation (ICU) released the Q1 2026 earnings call transcript, detailing financial results, operational updates, and forward-looking guidance. Q1 2026 earnings transcript reveals financial performance, strategic initiatives, and guidance directly impacting ICU's market trajectory and investor sentiment.

SeaStar Medical Holding Corporation (ICU) released the full transcript of its Q1 2026 earnings call. Q1 2026 earnings call transcript details financial results, operational updates, and strategic guidance significantly impacting ICU's future performance and investor sentiment.

SeaStar Medical Holding Corporation (ICU) reported first quarter financial results and provided business updates. Q1 financial results and business updates significantly affect financial performance, investor sentiment, and strategic trajectory.

SeaStar Medical Holding Corporation held its Q1 2026 earnings call, covering quarterly financial results, operational updates, and forward-looking guidance. Quarterly earnings call delivers financial metrics and outlook that can shift near-term investor views but rarely reshape long-term company trajectory.

SeaStar Medical Holding Corporation (ICU) announced poster presentations at the AKI & CRRT 2026 conference highlighting SAVE Registry data and the mechanism of action for its Selective Cytopheretic Device (SCD). Poster presentations of SAVE Registry data and SCD mechanism strengthen clinical validation for ICU's AKI treatment, likely influencing investor sentiment and competitive positioning.

SeaStar Medical presented new positive data from the QUELIMMUNE SAVE Registry and an analysis of the Selective Cytopheretic Device (SCD) therapy's unique immunomodulatory mechanism at the AKI & CRRT 2026 conference. Showcasing positive registry data and novel therapy mechanism at a major conference advances clinical validation and could significantly enhance market perception and funding prospects.

SeaStar Medical Holding Corp (ICU) reported strong revenue growth in Q4 2025 earnings call highlights. Strong revenue growth signals major positive shift in financial performance and investor sentiment for ICU.

SeaStar Medical Holding Corporation (ICU) reported fourth quarter and full year 2025 financial results and provided business updates. Full-year financial results and business updates represent major disclosures that can significantly sway investor sentiment and stock trajectory.

SeaStar Medical Holding Corporation (ICU) completed the FDA enrollment requirement for the SAVE Surveillance Registry evaluating QUELIMMUNE safety in pediatric acute kidney injury (AKI) patients. FDA enrollment completion marks a key regulatory milestone advancing QUELIMMUNE toward pediatric AKI approval and enhancing ICU's clinical validation and investor appeal.

SeaStar Medical Holding Corporation announced the publication of a study validating the real-world clinical impact of its QUELIMMUNE™ therapy in pediatric acute kidney injury (AKI). The study highlights significant improvements in patient outcomes, reinforcing the potential of QUELIMMUNE™ as a transformative treatment option in this critical area of pediatric healthcare. This publication is expected to enhance the company's credibility and market position in the medical field. The validation of QUELIMMUNE™ in a critical healthcare area is likely to significantly impact future performance and investor sentiment.

SeaStar Medical Holding Corporation announced the publication of positive real-world experience regarding its QUELIMMUNE™ therapy for pediatric acute kidney injury (AKI) in the journal Pediatric Nephrology. The study highlights the therapy's effectiveness and potential benefits for children suffering from AKI, marking a significant advancement in pediatric nephrology. The publication of positive real-world data for QUELIMMUNE™ therapy is likely to significantly enhance the company's market position and investor sentiment.

Eric Schlorff, CEO of SeaStar Medical Holding Corporation, discusses the company's strategic direction, recent developments, and future plans. He highlights advancements in their medical technologies aimed at improving patient outcomes and the company's commitment to innovation in the healthcare sector. Schlorff emphasizes the importance of partnerships and collaborations to enhance product offerings and market reach, while also addressing challenges faced in the industry. Significant strategic moves and advancements in medical technologies are expected to alter the company's trajectory and investor sentiment.

SeaStar Medical Holding Corporation (ICU) is focused on innovative solutions for acute kidney injury (AKI) patients. The company is initiating coverage, highlighting its critical care innovations aimed at improving patient outcomes. ICU's technology is positioned to address significant unmet needs in the AKI treatment landscape, potentially enhancing its market presence and financial performance. Innovative solutions for AKI patients could significantly alter the company's trajectory and investor sentiment.

SeaStar Medical Holding Corporation announced key milestones for 2026, focusing on advancements in its medical technologies aimed at improving patient outcomes. The company outlined specific goals and timelines for product development and regulatory submissions, signaling a commitment to innovation in the healthcare sector. These milestones are expected to enhance the company's market position and drive future growth. The outlined milestones indicate significant strategic moves that could alter the company's trajectory and investor sentiment.

SeaStar Medical Holding Corporation (ICU) is set to present at the upcoming Biotech Showcase 2026 Investor Conference, highlighting its commitment to advancing innovative medical solutions. The conference will provide a platform for the company to engage with investors and showcase its developments in the biotech sector. Participation in a prominent investor conference can enhance visibility and attract potential investment, impacting market sentiment.

SeaStar Medical Holding Corporation announced a 1-for-10 reverse stock split aimed at increasing the per-share price of its common stock. The reverse split is intended to help the company meet the minimum bid price requirement for continued listing on the Nasdaq. The split will take effect on a specified date, and shareholders will receive one new share for every ten shares they currently own. This move is part of the company's strategy to enhance its market position and investor appeal. The reverse stock split may improve market perception and compliance with listing requirements, but its overall impact on long-term performance remains limited.

SeaStar Medical Holding Corporation received FDA approval to reduce the mandatory enrollment for its SAVE Surveillance Registry, which evaluates the safety of QUELIMMUNE™ for pediatric acute kidney injury (AKI). This regulatory change is expected to streamline the process and potentially accelerate the development and assessment of QUELIMMUNE™ in pediatric patients. FDA approval for reduced enrollment is a significant regulatory change that could enhance the development timeline and market potential for QUELIMMUNE™.

SeaStar Medical Holding Corporation has appointed Michael Messinger as Chief Financial Officer. Messinger brings extensive experience in finance and operations, having previously held senior roles in various healthcare companies. His appointment is expected to strengthen SeaStar's financial strategy and support its growth initiatives. The appointment of a new CFO may influence financial performance and operational strategy but is not expected to drastically change the company's trajectory.

SeaStar Medical Holding Corporation (ICU) reported a significant revenue surge in Q3 2025, driven by increased demand for its innovative medical products. The company highlighted advancements in its product pipeline and positive market reception, which contributed to improved financial performance. Management expressed optimism about future growth prospects and strategic initiatives aimed at expanding market reach. The revenue surge and advancements in the product pipeline indicate a significant impact on future performance and investor sentiment.

SeaStar Medical Holding Corporation (ICU) reported its Q3 2025 earnings, highlighting key financial metrics and operational updates. The company discussed revenue growth, product development progress, and strategic initiatives aimed at enhancing market position. Management provided insights into future expectations and challenges, emphasizing ongoing efforts to innovate and expand within the medical sector. Significant strategic initiatives and product developments are expected to influence the company's future performance and market position.